Lam, Vi;
Best, Scott;
Kittai, Adam;
Orand, Kirsten;
Spurgeon, Stephen E.;
Liu, Tingting;
Danilov, Alexey V.
Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia
Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia
Beteiligte:
Lam, Vi;
Best, Scott;
Kittai, Adam;
Orand, Kirsten;
Spurgeon, Stephen E.;
Liu, Tingting;
Danilov, Alexey V.
Erschienen:
Wiley, 2022
Erschienen in:British Journal of Clinical Pharmacology
Beschreibung:
<jats:p>Spleen tyrosine kinase (SYK) is indispensable in B‐cell receptor signalling. SYK inhibitor entospletinib demonstrated clinical efficacy in patients with chronic lymphocytic leukaemia (CLL). However, pharmacodynamic effects of SYK inhibition in CLL cells and immunomodulatory effects of B‐cell receptor‐signalling inhibitors in patients with CLL are poorly understood. We conducted a phase 2 trial of entospletinib in combination with obinutuzumab, an anti‐CD20 antibody, in 17 patients with relapsed/refractory CLL. Pharmacodynamic analysis demonstrated that treatment with entospletinib led to rapid downmodulation of pSTAT3 and the anti‐apoptotic protein MCL1 in CLL cells. Meanwhile, 6 months of combination therapy was accompanied by a reduction in interferon‐γ secretion in CD4<jats:sup>+</jats:sup> T‐cells and a reversal of exhausted phenotype, as evidenced by downregulation of PD‐1. Thus, SYK inhibition downmodulates MCL‐1 and partially restores T‐cell immunity in CLL. Trial registration number <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03010358">NCT03010358</jats:ext-link>.</jats:p>